A Phase 3 interventional study of PF-04965842 100 mg and PF-04965842 200 mg in Dermatitis, Dermatitis, Atopic and Eczema, sponsored by Pfizer. Completed at 235 sites in 21 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-09-20.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.
Responder criteria for randomization at week 12 are defined as a) achieving an IGA of clear (0) or almost clear (1) (on a 5 point scale), b) a reduction from IGA baseline of 2 or more points, and c) reaching an EASI-75 response compared to baseline. Flare requiring rescue treatment is defined as a loss of at least 50% of the EASI response at Week 12 and an IGA score of 2 or higher.
238 studies on the registry are indexed under Dermatitis; 34 are open to participants now.
This study's enrollment of 1,235 is above the median of 68 across 191 interventional studies indexed under Dermatitis.
Browse Dermatitis studies →Pfizer is the lead sponsor of 3,334 studies on the registry; 149 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind randomized treatment following open label run-in period.
Drug: PF-04965842 100 mg
Double-blind randomized treatment following open label run-in period.
Drug: PF-04965842 200 mg
Double-blind randomized treatment following open label run-in period.
Drug: Placebo
PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
Also known as: Abrocitinib
PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
Also known as: Abrocitinib
Placebo, administered as two tablets to be taken orally once daily for 40 weeks
Percentage of Participants With Loss of Response: Double-blind (DB) Period
Percentage of participants with loss of response requiring rescue treatment during double blind period was determined. Loss of response denoted as flare and was define as a loss of at least 50% of EASI total score at Week 12 and with an IGA score of 2 or higher. EASI quantifies severity of participant's atopic dermatitis (AD) based on both severity of lesion clinical signs and % of body surface area (BSA) affected. EASI is a composite scoring by AD clinical evaluator of degree of erythema, induration/papulation, excoriation, and lichenification for each of 4 body regions. EASI total score range from 0.0 to 72.0, with higher scores representing greater severity of AD. IGA assesses severity of AD on 5-point scale (0 to 4, higher scores = more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate and 4 = severe.
Time frame: From Day 1 of up to Week 40 of double blind period
Time to Loss of Response: Double-blind Period
Time (in days) to loss of response based on achieving IGA \>=2 was measured from date of first dose of randomized treatment until last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) and based on EASI, loss of at least 50% of EASI response at Week 12 and IGA score of 2 or higher. IGA assesses severity of AD on 5-point scale (0 to 4, higher scores=more severity), reflecting global consideration of erythema, induration and scaling with scores 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. EASI composite score evaluates degree of erythema, induration/papulation, excoriation, and lichenification.
Time frame: From date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) (maximum up to Week 40, visit window was extended +/- 45 Days due to COVID 19)
Time to First Loss of Response Based on Investigator's Global Assessment (IGA) Score of 2 or Higher: Double-blind Period
Time (in days) to loss of response based on achieving IGA \>=2 (for the first time) as measured from date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue). IGA assesses severity of AD on a 5-point scale (0 to 4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep, dark red lesions.
Time frame: From date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) (maximum up to Week 40, visit window +/- 7 Days)
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Weeks 12, 16, 28, 40, and 52: Double-blind Period
IGA assessed severity of AD on a 5-point scale (0 to 4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep dark red lesions.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=50% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) was scored separately for each of 4 body regions (head and neck \[h\], upper limbs \[u\], trunk \[t\] \[including axillae and groin\] and lower limbs \[l\] \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); where A = area score. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=75% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=90% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=100% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percentage of Participants With Greater Than or Equal 4 Points Improvement in the Numerical Rating Scale (NRS) for Severity of Pruritus From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period
Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated worse disease status.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percent Change From Baseline in Body Surface Area (BSA) at Weeks 12, 16, 28, 40 and 52: Double-blind Period
4 body regions evaluated: head and neck, upper limbs, trunk (including axillae, groin/genitals), lower limbs (including buttocks) excluding scalp, palms, soles. BSA calculated by handprint method. Number (No) of handprints (size of participant's hand with fingers in closed position) fitting in affected area of a body region was estimated. Maximum No of handprints were 10, 20, 30, 40 for head and neck, upper limbs, trunk, and lower limbs respectively. Surface area (SA) of body region equivalent to 1 handprint: 1 handprint=10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. %Change BSA for a body region was calculated as=total No of handprints in a body region\* %SA equivalent to 1 handprint. %BSA for an individual: arithmetic mean of %BSA of all 4 body regions, ranged from 0-100%, higher values=greater AD severity.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3); severity scores added to give B (0-18). C: pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch and Sleep Loss at Weeks 12, 16, 28, 40 and 52: Double-blind Period
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region-head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percentage of Participants With >=50% Improvement From Baseline in Scoring Atopic Dermatitis (SCORAD) Response at Weeks 12, 16, 28, 40 and 52: Double-blind Period
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percentage of Participants With >=75% Improvement From Baseline in Scoring Atopic Dermatitis (SCORAD) Response at Weeks 12, 16, 28, 40 and 52: Double-blind Period
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period
IGA assessed severity of AD on a 5-point scale (0-4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0=clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep, dark red lesions.
Time frame: Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12
Percent Change From Rescue Baseline in Total Eczema Area and Severity Index (EASI) Score at Rescue Weeks 2, 4, 8 and 12: Rescue Period
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
Time frame: Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12
Percentage of Participants Achieving Greater Than or Equal to 4 Points Improvement From Rescue Baseline in Peak Pruritus Numeric Rating Scale (PP-NRS) at Rescue Weeks 2, 4, 8 and 12: Rescue Period
Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated greater severity.
Time frame: Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12
Percent Change From Rescue Baseline in Percent Body Surface Area (BSA) at Rescue Weeks 2, 4, 8 and 12: Rescue Period
4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin/genitals) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Overall % BSA for an individual % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.
Time frame: Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12
Percent Change From Rescue Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analog Scale (VAS) Score of Itch and Sleep Loss at Rescue Weeks 2, 4, 8 and 12: Rescue Period
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Time frame: Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12
Percentage of Participants With 50% Improvement in Scoring Atopic Dermatitis (SCORAD) From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Time frame: Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12
Percentage of Participants With 75% Improvement in Scoring Atopic Dermatitis (SCORAD) From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Time frame: Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12
Percentage of Participants Achieving Patient Global Assessment (PtGA) Response of 'Clear (0)' or 'Almost Clear (1)' and Greater Than or Equal to 2 Points Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period
Participant responded to the following question: "Overall, how would you describe your Atopic Dermatitis right now?" on a 5-point scale: 0= clear; 1= almost clear; 2= mild; 3= moderate; and 4= severe. Higher scores indicated more severity.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Change From Baseline in Dermatology Life Quality Index (DLQI) Score for Adults at Weeks 12, 16, 28, 40 and 52: Double-blind Period
DLQI was a 10-item questionnaire that measures the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score for Adolescents at Weeks 12, 16, 28, 40 and 52: Double-blind Period
CDLQI is a 10-item questionnaire that measures the impact of skin disease on adolescents (aged 12-17 years) quality of life over the last week. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all , 1 = only a little, 2 = quite a lot, 3 = very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give CDLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety Scale at Weeks 12, 16, 28, 40 and 52: Double-blind Period
HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression Scale at Weeks 12, 16, 28, 40 and 52: Double-blind Period
HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Change From Baseline in Patient Oriented Eczema Measure (POEM) Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period
POEM was a 7-item participant reported outcome (PRO) measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item scored as following: no days = 0, 1-2 days = 1, 3-4 days = 2, 5-6 days = 3 and, every day = 4. The total POEM score ranges from 0 to 28, where higher score indicated greater severity.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period
PSAAD is a daily participant reported symptom electronic diary. Participants rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin \[darker or lighter\], bleeding from skin, seeping or oozing fluid from skin \[other than blood\], and skin swelling). Participants had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition.
Time frame: Baseline, Weeks 12, 16, 28, 40 and 52
Total 1235 participants were enrolled in 236 sites in 21 countries. Study started from 11 June 2018 and completed on 07 October 2020.
| Milestone | PF-04965842 200 mg OL | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | PF-04965842 200 mg Rescue Period |
|---|---|---|---|---|---|
| Started | 1235 | 0 | 0 | 0 | 0 |
| Treated | 1233 | 0 | 0 | 0 | 0 |
| Completed | 798 | 0 | 0 | 0 | 0 |
| Not completed | 437 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 48 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 315 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 13 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 40 | 0 | 0 | 0 | 0 |
| Withdrew: Medication error without associated adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 2 | 0 | 0 | 0 | 0 |
| Milestone | PF-04965842 200 mg OL | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | PF-04965842 200 mg Rescue Period |
|---|---|---|---|---|---|
| Started | 0 | 267 | 265 | 266 | 0 |
| Participants entered rescue period | 0 | 208 | 109 | 44 | 0 |
| Completed after entering rescue period | 0 | 201 | 99 | 41 | 0 |
| Completed without entering rescue period | 0 | 43 | 134 | 187 | 0 |
| Completed | 0 | 251 | 243 | 231 | 0 |
| Not completed | 0 | 16 | 22 | 35 | 0 |
| Withdrew: Adverse event | 0 | 6 | 7 | 19 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 5 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 9 | 6 | 10 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 1 | 0 |
| Milestone | PF-04965842 200 mg OL | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | PF-04965842 200 mg Rescue Period |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 361 |
| Met protocol-defined flare criteria | 0 | 0 | 0 | 0 | 351 |
| Completed | 0 | 0 | 0 | 0 | 341 |
| Not completed | 0 | 0 | 0 | 0 | 20 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 |
Percentage of participants with loss of response requiring rescue treatment during double blind period was determined. Loss of response denoted as flare and was define as a loss of at least 50% of EASI total score at Week 12 and with an IGA score of 2 or higher. EASI quantifies severity of participant's atopic dermatitis (AD) based on both severity of lesion clinical signs and % of body surface area (BSA) affected. EASI is a composite scoring by AD clinical evaluator of degree of erythema, induration/papulation, excoriation, and lichenification for each of 4 body regions. EASI total score range from 0.0 to 72.0, with higher scores representing greater severity of AD. IGA assesses severity of AD on 5-point scale (0 to 4, higher scores = more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate and 4 = severe.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Percentage of Participants With Loss of Response: Double-blind (DB) Period | 77.5 | 39.6 | 16.5 |
Time (in days) to loss of response based on achieving IGA \>=2 (for the first time) as measured from date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue). IGA assesses severity of AD on a 5-point scale (0 to 4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep, dark red lesions.
| days | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Time to First Loss of Response Based on Investigator's Global Assessment (IGA) Score of 2 or Higher: Double-blind Period | 27.0 ± 26.0 | 78.0 ± 32.0 | 201.0 ± 177.0 |
IGA assessed severity of AD on a 5-point scale (0 to 4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep dark red lesions.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 99.6 (98.9 to 100.0) | 99.6 (98.9 to 100.0) | 99.2 (98.2 to 100.0) |
| Week 16 | 15.4 (11.0 to 19.7) | 55.5 (49.5 to 61.5) | 77.8 (72.8 to 82.8) |
| Week 28 | 10.5 (6.8 to 14.2) | 45.0 (39.0 to 51.0) | 61.8 (55.9 to 67.7) |
| Week 40 | 10.6 (6.9 to 14.3) | 42.3 (36.3 to 48.3) | 57.1 (51.1 to 63.2) |
| Week 52 | 11.7 (7.9 to 15.6) | 36.8 (30.9 to 42.7) | 54.1 (48.0 to 60.2) |
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) was scored separately for each of 4 body regions (head and neck \[h\], upper limbs \[u\], trunk \[t\] \[including axillae and groin\] and lower limbs \[l\] \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); where A = area score. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.6 to 100.0) |
| Week 16 | 40.8 (34.9 to 46.7) | 83.3 (78.8 to 87.8) | 96.2 (94.0 to 98.5) |
| Week 28 | 22.8 (17.8 to 27.9) | 68.1 (62.4 to 73.7) | 85.9 (81.7 to 90.1) |
| Week 40 | 16.6 (12.1 to 21.1) | 57.3 (51.3 to 63.3) | 74.9 (69.6 to 80.2) |
| Week 52 | 15.9 (11.5 to 20.3) | 50.8 (44.7 to 56.9) | 71.2 (65.7 to 76.7) |
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 99.2 (98.2 to 100.0) | 100.0 (98.6 to 100.0) | 99.6 (98.9 to 100.0) |
| Week 16 | 27.0 (21.6 to 32.3) | 76.0 (70.9 to 81.2) | 92.5 (89.3 to 95.7) |
| Week 28 | 18.0 (13.4 to 22.6) | 60.4 (54.4 to 66.3) | 80.5 (75.7 to 85.3) |
| Week 40 | 15.1 (10.8 to 19.4) | 54.2 (48.2 to 60.3) | 71.8 (66.3 to 77.3) |
| Week 52 | 14.0 (9.8 to 18.2) | 46.5 (40.4 to 52.6) | 65.8 (60.0 to 71.6) |
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 84.6 (80.2 to 88.9) | 87.1 (83.1 to 91.2) | 86.4 (82.3 to 90.5) |
| Week 16 | 13.9 (9.7 to 18.0) | 51.3 (45.3 to 57.4) | 77.1 (72.0 to 82.1) |
| Week 28 | 10.5 (6.8 to 14.2) | 46.9 (40.9 to 53.0) | 64.5 (58.7 to 70.3) |
| Week 40 | 12.1 (8.2 to 16.0) | 41.5 (35.5 to 47.5) | 58.7 (52.7 to 64.7) |
| Week 52 | 10.6 (6.9 to 14.3) | 37.6 (31.7 to 43.5) | 54.5 (48.4 to 60.6) |
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 30.5 (24.9 to 36.0) | 30.3 (24.8 to 35.8) | 28.3 (22.9 to 33.7) |
| Week 16 | 3.7 (1.5 to 6.0) | 15.2 (10.9 to 19.5) | 28.9 (23.5 to 34.4) |
| Week 28 | 4.1 (1.7 to 6.5) | 16.5 (12.0 to 21.1) | 30.2 (24.6 to 35.7) |
| Week 40 | 4.5 (2.0 to 7.0) | 15.8 (11.3 to 20.2) | 30.1 (24.5 to 35.7) |
| Week 52 | 4.5 (2.0 to 7.1) | 18.6 (13.9 to 23.4) | 28.8 (23.3 to 34.3) |
Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated worse disease status.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 82.2 (77.2 to 87.1) | 84.0 (79.3 to 88.6) | 81.9 (76.9 to 86.9) |
| Week 16 | 15.9 (11.4 to 20.4) | 54.6 (48.4 to 60.7) | 75.6 (70.3 to 80.9) |
| Week 28 | 11.6 (7.7 to 15.5) | 45.0 (38.9 to 51.2) | 66.9 (61.0 to 72.8) |
| Week 40 | 10.1 (6.4 to 13.8) | 39.4 (33.4 to 45.4) | 55.7 (49.5 to 61.9) |
| Week 52 | 8.3 (4.9 to 11.7) | 27.6 (21.7 to 33.6) | 49.0 (42.2 to 55.9) |
4 body regions evaluated: head and neck, upper limbs, trunk (including axillae, groin/genitals), lower limbs (including buttocks) excluding scalp, palms, soles. BSA calculated by handprint method. Number (No) of handprints (size of participant's hand with fingers in closed position) fitting in affected area of a body region was estimated. Maximum No of handprints were 10, 20, 30, 40 for head and neck, upper limbs, trunk, and lower limbs respectively. Surface area (SA) of body region equivalent to 1 handprint: 1 handprint=10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. %Change BSA for a body region was calculated as=total No of handprints in a body region\* %SA equivalent to 1 handprint. %BSA for an individual: arithmetic mean of %BSA of all 4 body regions, ranged from 0-100%, higher values=greater AD severity.
| percent change | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Change at Week 12 | -95.6 (-100.0 to -88.5) | -96.7 (-100.0 to -91.5) | -96.7 (-100.0 to -89.2) |
| Change at Week 16 | -68.5 (-89.8 to -37.5) | -90.9 (-97.6 to -78.3) | -96.3 (-100.0 to -88.7) |
| Change at Week 28 | -85.2 (-95.8 to -63.5) | -93.8 (-99.5 to -81.4) | -96.4 (-100.0 to -85.7) |
| Change at Week 40 | -91.2 (-100.0 to -77.9) | -95.8 (-100.0 to -83.5) | -96.8 (-100.0 to -88.8) |
| Change at Week 52 | -91.5 (-100.0 to -77.9) | -96.9 (-100.0 to -83.4) | -96.9 (-100.0 to -88.2) |
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3); severity scores added to give B (0-18). C: pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
| percent change | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Change at Week 12 | -84.0 (-94.7 to -73.5) | -84.4 (-95.2 to -74.9) | -84.4 (-93.8 to -74.2) |
| Change at Week 16 | -50.4 (-68.3 to -32.1) | -71.7 (-87.8 to -60.5) | -83.6 (-95.1 to -70.6) |
| Change at Week 28 | -63.4 (-81.9 to -48.3) | -77.8 (-90.2 to -62.6) | -83.8 (-97.4 to -66.4) |
| Change at Week 40 | -74.4 (-89.5 to -60.6) | -77.1 (-94.1 to -64.3) | -84.6 (-98.6 to -68.4) |
| Change at Week 52 | -73.3 (-89.8 to -58.0) | -82.5 (-97.7 to -64.1) | -83.2 (-100.0 to -69.1) |
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region-head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
| units on a scale | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Pruritus VAS: Change at Week 12 | -6.1 (-6.3 to -5.9) | -6.1 (-6.3 to -5.9) | -6.1 (-6.3 to -5.9) |
| Pruritus VAS: Change at Week 16 | 3.4 (3.0 to 3.7) | 1.2 (1.0 to 1.5) | 0.2 (-0.1 to 0.4) |
| Pruritus VAS: Change at Week 28 | 2.4 (1.9 to 2.9) | 1.1 (0.8 to 1.4) | 0.5 (0.3 to 0.8) |
| Pruritus VAS: Change at Week 40 | 2.2 (1.6 to 2.8) | 1.2 (0.9 to 1.6) | 0.4 (0.1 to 0.7) |
| Pruritus VAS: Change at Week 52 | 1.8 (1.2 to 2.4) | 1.3 (0.9 to 1.6) | 0.5 (0.2 to 0.8) |
| Sleep Loss VAS: Change at Week 12 | -5.0 (-5.2 to -4.8) | -5.0 (-5.2 to -4.8) | -5.1 (-5.3 to -4.9) |
| Sleep Loss VAS: Change at Week 16 | 2.3 (2.0 to 2.6) | 0.5 (0.3 to 0.8) | 0.0 (-0.2 to 0.2) |
| Sleep Loss VAS: Change at Week 28 | 1.3 (0.9 to 1.7) | 0.6 (0.4 to 0.9) | 0.2 (0.0 to 0.4) |
| Sleep Loss VAS: Change at Week 40 | 1.3 (0.8 to 1.8) | 0.6 (0.3 to 0.9) | 0.2 (0.0 to 0.4) |
| Sleep Loss VAS: Change at Week 52 | 1.2 (0.7 to 1.8) | 0.9 (0.5 to 1.2) | 0.3 (0.0 to 0.5) |
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 97.4 (95.4 to 99.3) | 98.5 (97.0 to 100.0) | 97.0 (94.9 to 99.0) |
| Week 16 | 25.6 (20.3 to 30.8) | 72.0 (66.6 to 77.4) | 89.1 (85.4 to 92.8) |
| Week 28 | 15.8 (11.4 to 20.2) | 56.8 (50.7 to 62.8) | 75.7 (70.5 to 80.9) |
| Week 40 | 14.4 (10.2 to 18.6) | 51.2 (45.1 to 57.2) | 69.0 (63.3 to 74.6) |
| Week 52 | 14.8 (10.5 to 19.1) | 44.6 (38.5 to 50.6) | 65.8 (60.0 to 71.6) |
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 73.6 (68.3 to 78.9) | 75.0 (69.8 to 80.2) | 71.3 (65.9 to 76.8) |
| Week 16 | 9.4 (5.9 to 12.9) | 38.3 (32.4 to 44.1) | 67.3 (61.7 to 72.9) |
| Week 28 | 7.5 (4.3 to 10.7) | 37.8 (31.9 to 43.7) | 56.3 (50.3 to 62.3) |
| Week 40 | 8.3 (5.0 to 11.7) | 32.7 (27.0 to 38.4) | 47.7 (41.6 to 53.8) |
| Week 52 | 7.6 (4.4 to 10.8) | 31.8 (26.1 to 37.5) | 45.9 (39.8 to 52.0) |
IGA assessed severity of AD on a 5-point scale (0-4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0=clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep, dark red lesions.
| percentage of participants | PF-04965842 200 mg Rescue Period |
|---|---|
| Rescue Week 2 | 30.7 (25.8 to 35.7) |
| Rescue Week 4 | 54.6 (49.3 to 59.9) |
| Rescue Week 8 | 60.2 (55.0 to 65.4) |
| Rescue Week 12 | 64.1 (59.0 to 69.2) |
EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
| percent change | PF-04965842 200 mg Rescue Period |
|---|---|
| Change at Rescue Week 2 | -71.1 ± -73.7 |
| Change at Rescue Week 4 | -82.0 ± -84.2 |
| Change at Rescue Week 8 | -86.4 ± -88.2 |
| Change at Rescue Week 12 | -87.3 ± -89.4 |
Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated greater severity.
| percentage of participants | PF-04965842 200 mg Rescue Period |
|---|---|
| Rescue Week 2 | 56.6 (50.7 to 62.5) |
| Rescue Week 4 | 63.2 (57.2 to 69.2) |
| Rescue Week 8 | 67.2 (61.4 to 73.0) |
| Rescue Week 12 | 56.2 (48.3 to 64.1) |
4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin/genitals) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Overall % BSA for an individual % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.
| percent change | PF-04965842 200 mg Rescue Period |
|---|---|
| Change at Rescue Week 2 | -62.8 (-66.0 to -59.6) |
| Change at Rescue Week 4 | -76.4 (-79.1 to -73.7) |
| Change at Rescue Week 8 | -82.1 (-84.5 to -79.6) |
| Change at Rescue Week 12 | -83.3 (-86.0 to -80.5) |
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
| percent change | PF-04965842 200 mg Rescue Period |
|---|---|
| Pruritus VAS: Change at Rescue Week 2 | -57.3 ± -61.7 |
| Pruritus VAS: Change at Rescue Week 4 | -67.5 ± -71.3 |
| Pruritus VAS: Change at Rescue Week 8 | -68.6 ± -73.6 |
| Pruritus VAS: Change at Rescue Week 12 | -67.3 ± -72.8 |
| Sleep Loss VAS: Change at Rescue Week 2 | -62.5 ± -69.1 |
| Sleep Loss VAS: Change at Rescue Week 4 | -72.4 ± -78.6 |
| Sleep Loss VAS: Change at Rescue Week 8 | -75.8 ± -82.0 |
| Sleep Loss VAS: Change at Rescue Week 12 | -74.5 ± -81.4 |
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
| percentage of participants | PF-04965842 200 mg Rescue Period |
|---|---|
| Rescue Week 2 | 55.0 (49.6 to 60.3) |
| Rescue Week 4 | 76.1 (71.6 to 80.6) |
| Rescue Week 8 | 79.6 (75.3 to 83.9) |
| Rescue Week 12 | 79.8 (75.5 to 84.1) |
SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
| percentage of participants | PF-04965842 200 mg Rescue Period |
|---|---|
| Rescue Week 2 | 16.9 (12.9 to 21.0) |
| Rescue Week 4 | 33.9 (28.9 to 39.0) |
| Rescue Week 8 | 44.4 (39.1 to 49.7) |
| Rescue Week 12 | 45.4 (40.1 to 50.7) |
Participant responded to the following question: "Overall, how would you describe your Atopic Dermatitis right now?" on a 5-point scale: 0= clear; 1= almost clear; 2= mild; 3= moderate; and 4= severe. Higher scores indicated more severity.
| percentage of participants | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Week 12 | 61.7 (55.7 to 67.7) | 64.5 (58.7 to 70.3) | 59.7 (53.7 to 65.7) |
| Week 16 | 5.9 (3.0 to 8.8) | 29.8 (24.2 to 35.3) | 48.3 (42.2 to 54.3) |
| Week 28 | 6.3 (3.3 to 9.3) | 30.9 (25.3 to 36.5) | 46.9 (40.8 to 53.0) |
| Week 40 | 7.5 (4.3 to 10.8) | 26.1 (20.7 to 31.4) | 42.0 (35.9 to 48.1) |
| Week 52 | 7.6 (4.3 to 10.8) | 25.8 (20.4 to 31.1) | 39.7 (33.6 to 45.8) |
DLQI was a 10-item questionnaire that measures the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
| units on a scale | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Change at Week 12 | -13.5 ± -13.9 | -13.4 ± -13.8 | -13.5 ± -14.0 |
| Change at Week 16 | 6.9 ± 6.1 | 1.9 ± 1.2 | 0.4 ± -0.2 |
| Change at Week 28 | 6.1 ± 5.0 | 2.1 ± 1.4 | 0.9 ± 0.3 |
| Change at Week 40 | 4.4 ± 3.0 | 2.5 ± 1.7 | 1.1 ± 0.5 |
| Change at Week 52 | 3.6 ± 2.1 | 2.8 ± 2.0 | 0.9 ± 0.2 |
CDLQI is a 10-item questionnaire that measures the impact of skin disease on adolescents (aged 12-17 years) quality of life over the last week. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all , 1 = only a little, 2 = quite a lot, 3 = very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give CDLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
| units on a scale | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Change at Week 12 | -9.8 ± -10.6 | -9.2 ± -10.0 | -9.3 ± -10.2 |
| Change at Week 16 | 5.9 ± 4.4 | 1.7 ± 0.5 | -0.3 ± -1.4 |
| Change at Week 28 | 1.5 ± -0.2 | 1.6 ± 0.6 | 0.4 ± -0.5 |
| Change at Week 40 | 2.1 ± 0.3 | 1.7 ± 0.7 | 0.0 ± -0.9 |
| Change at Week 52 | 2.3 ± 0.3 | 1.3 ± 0.0 | 0.4 ± -0.6 |
Time (in days) to loss of response based on achieving IGA \>=2 was measured from date of first dose of randomized treatment until last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) and based on EASI, loss of at least 50% of EASI response at Week 12 and IGA score of 2 or higher. IGA assesses severity of AD on 5-point scale (0 to 4, higher scores=more severity), reflecting global consideration of erythema, induration and scaling with scores 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. EASI composite score evaluates degree of erythema, induration/papulation, excoriation, and lichenification.
| days | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Time to Loss of Response: Double-blind Period | 28.0 (28.0 to 29.0) | 323.0 (282.0 to 323.0) | NA (NA to NA) |
HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety.
| units on a scale | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Change at Week 12 | -2.7 ± -3.0 | -2.6 ± -2.9 | -2.6 ± -2.9 |
| Change at Week 16 | 1.4 ± 1.0 | 0.3 ± 0.0 | 0.0 ± -0.3 |
| Change at Week 28 | 1.0 ± 0.5 | 0.4 ± 0.1 | 0.1 ± -0.2 |
| Change at Week 40 | 1.0 ± 0.4 | 0.4 ± 0.1 | 0.1 ± -0.3 |
| Change at Week 52 | 0.8 ± 0.2 | 0.4 ± 0.1 | 0.2 ± -0.1 |
HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms.
| units on a scale | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Change at Week 12 | -2.0 ± -2.3 | -1.6 ± -1.9 | -1.7 ± -2.0 |
| Change at Week 16 | 1.4 ± 1.0 | 0.0 ± -0.3 | 0.0 ± -0.2 |
| Change at Week 28 | 0.7 ± 0.2 | 0.3 ± 0.0 | 0.1 ± -0.2 |
| Change at Week 40 | 0.8 ± 0.2 | -0.1 ± -0.4 | 0.2 ± -0.1 |
| Change at Week 52 | 0.4 ± -0.1 | -0.1 ± -0.4 | 0.1 ± -0.2 |
POEM was a 7-item participant reported outcome (PRO) measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item scored as following: no days = 0, 1-2 days = 1, 3-4 days = 2, 5-6 days = 3 and, every day = 4. The total POEM score ranges from 0 to 28, where higher score indicated greater severity.
| units on a scale | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Change at Week 12 | -15.4 ± -16.0 | -15.8 ± -16.4 | -15.4 ± -16.0 |
| Change at Week 16 | 9.8 ± 8.9 | 3.7 ± 3.0 | 0.6 ± -0.1 |
| Change at Week 28 | 8.3 ± 6.9 | 3.7 ± 2.8 | 1.6 ± 0.8 |
| Change at Week 40 | 7.4 ± 5.8 | 4.8 ± 3.9 | 1.9 ± 1.1 |
| Change at Week 52 | 7.3 ± 5.4 | 4.9 ± 3.8 | 2.2 ± 1.3 |
PSAAD is a daily participant reported symptom electronic diary. Participants rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin \[darker or lighter\], bleeding from skin, seeping or oozing fluid from skin \[other than blood\], and skin swelling). Participants had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition.
| units on a scale | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB |
|---|---|---|---|
| Change at Week 12 | -4.1 ± -4.3 | -4.2 ± -4.4 | -4.2 ± -4.4 |
| Change at Week 16 | 2.1 ± 1.9 | 0.8 ± 0.6 | 0.1 ± -0.1 |
| Change at Week 28 | 2.3 ± 2.0 | 1.0 ± 0.8 | 0.1 ± -0.1 |
| Change at Week 40 | 2.0 ± 1.7 | 1.0 ± 0.8 | 0.3 ± 0.0 |
| Change at Week 52 | 1.9 ± 1.5 | 1.2 ± 0.9 | 0.2 ± 0.0 |
Collected over From screening up to 28 days after last dose of study treatment (maximum up to Week 56). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-04965842 200 mg OL | 1/1,233 (0.1%) | 20/1,233 (1.6%) | 482/1,233 (39.1%) |
| PF-04965842 200 mg OL to Placebo DB | 0/267 (0%) | 3/267 (1.1%) | 158/267 (59.2%) |
| PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | 0/265 (0%) | 9/265 (3.4%) | 130/265 (49.1%) |
| PF-04965842 200 mg OL to PF-04965842 200 mg DB | 0/266 (0%) | 14/266 (5.3%) | 152/266 (57.1%) |
| PF-04965842 200 mg Rescue Period | 0/351 (0%) | 4/351 (1.1%) | 75/351 (21.4%) |
| Event | PF-04965842 200 mg OL | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | PF-04965842 200 mg Rescue Period |
|---|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 3/1233 | 0/267 | 1/265 | 1/266 | 2/351 |
| Retinal vein thrombosisEye disorders | 0/1233 | 0/267 | 1/265 | 0/266 | 0/351 |
| MyositisMusculoskeletal and connective tissue disorders | 1/1233 | 0/267 | 1/265 | 0/266 | 0/351 |
| HypokalaemiaMetabolism and nutrition disorders | 1/1233 | 0/267 | 1/265 | 0/266 | 0/351 |
| Eczema herpeticumInfections and infestations | 0/1233 | 0/267 | 1/265 | 1/266 | 0/351 |
| PharyngitisInfections and infestations | 1/1233 | 0/267 | 1/265 | 0/266 | 1/351 |
| PneumoniaInfections and infestations | 1/1233 | 1/267 | 1/265 | 0/266 | 0/351 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1233 | 0/267 | 1/265 | 0/266 | 0/351 |
| Chest painGeneral disorders | 1/1233 | 0/267 | 1/265 | 0/266 | 0/351 |
| Vitello-intestinal duct remnantCongenital, familial and genetic disorders | 0/1233 | 0/267 | 0/265 | 1/266 | 0/351 |
| Event | PF-04965842 200 mg OL | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | PF-04965842 200 mg Rescue Period |
|---|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 45/1233 | 88/267 | 56/265 | 36/266 | 13/351 |
| NauseaGastrointestinal disorders | 199/1233 | 44/267 | 35/265 | 49/266 | 12/351 |
| HeadacheNervous system disorders | 119/1233 | 31/267 | 24/265 | 31/266 | 12/351 |
| AcneSkin and subcutaneous tissue disorders | 68/1233 | 19/267 | 22/265 | 31/266 | 7/351 |
| NasopharyngitisInfections and infestations | 77/1233 | 26/267 | 27/265 | 28/266 | 17/351 |
| Upper respiratory tract infectionInfections and infestations | 63/1233 | 26/267 | 22/265 | 22/266 | 21/351 |
| Blood creatine phosphokinase increasedInvestigations | 43/1233 | 11/267 | 18/265 | 25/266 | 9/351 |
| VomitingGastrointestinal disorders | 42/1233 | 7/267 | 12/265 | 15/266 | 4/351 |
Full analysis set-randomized (FAS-RA) included as all participants who were randomized at Week 12 and received at least 1 dose of study medication within Double-blind (DB) phase.
| Age, Customized(Participants) | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | Total |
|---|---|---|---|---|
| <18 years | 49 | 49 | 47 | 145 |
| Between 18 and 65 years | 210 | 206 | 207 | 623 |
| >=65 years | 8 | 10 | 12 | 30 |
| Sex: Female, Male(Participants) | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | Total |
|---|---|---|---|---|
| Female | 126 | 117 | 116 | 359 |
| Male | 141 | 148 | 150 | 439 |
| Ethnicity (NIH/OMB)(Participants) | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | Total |
|---|---|---|---|---|
| Hispanic or Latino | 65 | 62 | 52 | 179 |
| Not Hispanic or Latino | 200 | 203 | 214 | 617 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | PF-04965842 200 mg OL to Placebo DB | PF-04965842 200 mg OL to PF-04965842 100 mg+Placebo DB | PF-04965842 200 mg OL to PF-04965842 200 mg DB | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 2 | 1 | 7 |
| Asian | 38 | 41 | 45 | 124 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 14 | 9 | 10 | 33 |
| White | 209 | 208 | 204 | 621 |
| More than one race | 2 | 3 | 5 | 10 |
| Unknown or Not Reported | 0 | 2 | 1 | 3 |
Showing the first 100 of 235 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2018 to primary completion in Sep 2020, 26 months.
Results were first posted in Sep 2021, 1 year after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Dermatitis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 26 months is above that.
Counting every sponsor, half of 29 studies reached it within 20 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib